LXXGF - LXXGF STOCK NEWS

LexaGene Holdings Inc. (OTCQB: LXXGF) has partnered with Ethos Discovery to enhance the test menu of the MiQLab™ System. The MiQLab™ Bacterial and AMR Test, which effectively diagnoses urinary tract infections in pets, forms the foundation for this expansion. LexaGene aims to develop new panels for severe pneumonia, diarrhea, and effusions, addressing significant medical needs. This collaboration is expected to drive sales and improve veterinary diagnostics through in-clinic rapid testing, reducing reliance on external labs.

LexaGene Holdings, Inc. (OTCQB: LXXGF) aims to list its shares on the Nasdaq Capital Market by the end of 2021, increasing accessibility for U.S. investors. The company has reserved the ticker symbol LXG and is preparing necessary documentation with Latham & Watkins LLP for SEC filing. LexaGene has engaged RSM US LLP for auditing services. Additionally, the company plans to enhance its market presence through a $150,000 digital media campaign with Native Ads, Inc. Executive officers will receive new stock options based on 2021 performance milestones linked to Nasdaq listing goals.

LexaGene Holdings (OTCQB: LXXGF) has announced the hiring of four new sales representatives to strengthen its efforts in the veterinary and contract drug manufacturing markets. CEO Dr. Jack Regan expressed optimism about the operational focus on the veterinary market, which is projected to grow to $4B. The company aims to improve diagnostics with its MiQLab™ system, enhancing in-clinic testing efficiency. Furthermore, the board approved grants totaling 396,000 restricted share units and options for directors, priced at CAD$0.66 per share, reflecting a positive market approach.

LexaGene Holdings, Inc. (OTCQB: LXXGF) hosted a private event showcasing its MiQLab diagnostic system for veterinarians, featuring Dr. Shelley Rankin from Penn Vet. The MiQLab demonstrated nearly 100% agreement with culture data from canine urine samples and effectively detected Staphylococcus in 91% of skin infection specimens. Additionally, 89% of methicillin-resistant samples showed the presence of the mecA gene. The studies confirm that MiQLab offers rapid pathogen detection, aiding veterinarians in effective antibiotic therapy decisions, improving clinical outcomes while combatting antibiotic resistance.

LexaGene Holdings (OTCQB: LXXGF) announced a corporate update from CEO Dr. Jack Regan. In late 2020, the company achieved significant sales in contract drug manufacturing and veterinary medicine following successful technology demonstrations. They have built 20 MiQLab systems and plan to manufacture 70 more. LexaGene is also focused on FDA applications for COVID-19 testing, with preliminary tests showing competitive sensitivity. An upcoming seminar for veterinarians will highlight their technology's capabilities.

LexaGene Holdings has raised approximately $3.6M CAD ($2.9M USD) from warrant exercises since the start of 2021. CEO Dr. Jack Regan reported that commercial sales and favorable outlook have positively impacted share prices. As COVID-19 restrictions ease, demand for the MiQLab is expected to rise, prompting hiring of additional sales reps in several U.S. regions. The company is also advancing its FDA EUA submission for COVID-19 testing, although its instruments are currently classified for research use only.

On February 12, 2021, LexaGene Holdings announced the resignation of Mr. Daryl Rebeck from his role as President and Board member, effective February 15, 2021. Stephen J. Mastrocola has been appointed to the Board, bringing nearly 40 years of accounting and auditing experience, particularly in the life sciences sector. CEO Dr. Jack Regan expressed gratitude for Rebeck's contributions while highlighting Mastrocola's capability to support LexaGene's growth objectives. The company specializes in rapid pathogen detection systems for various markets, including veterinary diagnostics and food safety.

LexaGene Holdings announced the successful configuration of its MiQLab system to detect UK and South African variants of SARS-CoV-2. These variants, noted for increased transmissibility and potential vaccine resistance, have been spreading in the US since late 2020. Dr. Jack Regan emphasized the system's unique open-access feature, allowing for rapid test deployment at point-of-care, enhancing containment efforts. The company is pursuing FDA EUA for COVID-19 testing, with current use limited to research until authorization is granted.

LexaGene Holdings, Inc. (OTCQB: LXXGF) provides a corporate update emphasizing its MiQLab™ pathogen detection system for veterinary and clinical usage. The company has resolved previous supply chain issues affecting system development and initiated an Early Access Program targeting key opinion leaders. LexaGene is pursuing FDA's Emergency Use Authorization (EUA) for its SARS-CoV-2 testing system, which faces stringent requirements. The treasury stands at $11.3M USD, ensuring operational support. A Clinical Evaluation Study Agreement has been signed with Dartmouth Hitchcock Medical Center for clinical study.